Skip to main content

Market Overview

Alere Announces Intent to Voluntarily Delist Series B Convertible Perpetual Preferred Stock from the NYSE Conditioned Upon the Completion of its Acquisition by Abbott


WALTHAM, Mass., Sept. 18, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) ("Alere"), today announced that it has submitted written notice to the New York Stock Exchange (the "NYSE") of its intention to voluntarily delist its Series B Convertible Perpetual Preferred Stock, par value $0.001 per share (the "Preferred Stock"), from the NYSE. The voluntary delisting is subject to and conditioned upon the completion of its acquisition by Abbott Laboratories, an Illinois corporation ("Abbott").

Abbott has informed Alere that it intends to consummate its offer to purchase all outstanding shares of the Preferred Stock (the "Offer") following the completion of the acquisition of Alere and upon satisfaction of all other conditions to the Offer, and thereafter to cancel all remaining shares of Preferred Stock in exchange for the liquidation preference, plus accrued but unpaid dividends, due on such shares of Preferred Stock. Following the delisting from the NYSE, the Preferred Stock will not be listed or registered on another national securities exchange or for quotation in a quotation medium.

Cautionary Statement Regarding Forward-Looking Statements  
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as "may," "could," "should," "would," "intend," "will," "expect," "anticipate," "believe," "estimate," "continue" or similar words. A number of important factors could cause actual results of Alere and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the risk factors detailed in Part I, Item 1A, "Risk Factors," of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 (as filed with the Securities and Exchange Commission on June 5, 2017) and other risk factors identified herein or from time to time in our periodic filings with the SEC. Readers should carefully review these risk factors, and should not place undue reliance on our forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this communication. We undertake no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

About Alere
Alere believes that when diagnosing and monitoring health conditions, Knowing now matters.™  Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. For more information on Alere, please visit

View original content:

SOURCE Alere Inc.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at